Skip to main content

Table 1 Demographic information, previous medications, and major outcomes for all patients

From: Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study

Patient Age Sex Duration of LN (years) LN class Previous medications and outcome Baseline TPU (g/24 h) Baseline prednisone (mg/d) Baseline creatine (μmol/L) Outcome of iguratimod treatment Follow-up time (weeks) Follow-up
1 30 F 13 IV → III§ Cyc → Cs* (CR → F) 5.17 15 43 PR 36 Discontinue (relapse)
     Cyc → LEF* (CR → F)       
     RTX (NR)       
2 45 F 12 III Pulse steroids (CR → F) 1.34 5 39 CR 84 Follow-up
     Cyc (PR → F)       
     MMF (NR)       
     TAC (NR)       
3 18 F 6 III + V MMF (PR → F) 2.33 10 75.5 PR 132 Follow-up
     TAC (PR → F)       
4 49 F 7 III + V Cyc → MMF* (CR → F) 4.92 0 63 PR 12 Discontinue (SAE)
     TAC (NR)       
5 55 F 18 III + V CYC (CR → AE) 3.33 10 77 CR 132 Follow-up
     LEF (NR)       
     Cyc (NR)       
     MMF (PR → F)       
     TAC (PR → F)       
6 29 F 6 IV + V TAC (NR) 3.48 0 35 CR 118 Follow-up
     MMF (PR → F)       
7 30 F 23 IV Cyc (CR → F) 6.01 15 72 PR 24 Discontinue (relapse)
     MMF (PR → F)       
     Cs (NR)       
     LEF (NR)       
8 31 F 5 III + VI → IV + V§ Cyc → MMF* (PR → F) 1.96 10 52 NR 28 NR
     TAC (NR)       
9 32 F 5 III + V Cyc (NR) 6.01 35 155 CR 36 Discontinue (extra-renal relapse)
     MMF (NR)       
     Sirolimius (NR)       
10 26 F 4 III → V§ Cyc (NR) 13.79 0 105 Lost 4 Lost to follow-up
     Cs (NR)       
     TAC (NR)       
11 46 M 6 III Cyc (PR → F) 6.24 10 72 PR 16 Follow-up
     MMF (PR → F)       
12 19 F 2 IV + V LEF (NR) 1.32 0 40.2 PR 36 Discontinue (relapse)
     MMF (PR → F)       
13 24 M 10 III + V Cyc (NR) 2.21 0 81 PR 32 Follow-up
     Cs (NR)       
     MMF (NR)       
     TAC (NR)       
     LEF + Tripterygium (NR)       
     Cyc (NR)       
14 34 F 6 IV Cyc → LEF* (CR → F) 2.57 10 43 CR 36 Follow-up
     Cs (CR → F)       
     MMF (NR)       
     TAC (NR)       
     AZA (NR)       
  1. TPU total proteinuria, Cyc cyclophosphamide, AZA azathioprine, Cs cyclosporine, LEF leflunomide, RTX rituximab, MMF mycophenolate mofetil, TAC tacrolimus, CR complete remission, PR partial remission, NR no response, SAE severe adverse event
  2. *Represents cyclophosphamide (typically 6 months) in sequence with other immunosuppressive agents. In this situation, the patients usually achieved PR or CR when the cyclophosphamide treatment ended
  3. §Patients agreed to repeated renal biopsies before iguratimod treatment